8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 4, 2021

AngioSoma, Inc.

(Exact name of registrant as specified in its charter)

Wyoming	333-170315	27-3480481
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2500 Wilcrest Drive, 3rd Floor

Houston, Texas 77042

(Address of principal executive offices)

832-781-8521
www.AngioSoma.com

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common	SOAN	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒              

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

AngioSoma, Inc. (the “Company”)’s subsidiary, SomaCeuticals, Inc., has defined its mission to bring its enhanced treatment for Multiple Sclerosis to patients worldwide.

As of February 4, 2021, the Company amended and restated its Exclusive Global Multiple Sclerosis License Agreement to give both parties a stronger and more robust platform to move synergistically forward to market and license U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020.

Multiple Sclerosis (MS) is a chronic disease in which the immune system of the individual attacks the central nervous system and affects the nerve cells. The disease can manifest with a wide range of neurological symptoms and can progress to total physical and cognitive disability. There are many different symptoms of MS, including fatigue, numbness, walking and balance problems, bladder dysfunction, bowel dysfunction, vision problems, dizziness and vertigo, sexual dysfunction, pain, cognitive dysfunction, emotional changes, depression and spasticity.

There is no known cure using current treatments and is the most common immune-mediated disorder affecting the central nervous system. With over 2.3 million people affected and with each individual spending approximately $70,000 per year, MS ranked eighth by drug invoice spending among the top therapeutic classes in the U.S. in 2016, representing nearly $19 billion in drug spending alone.

Item 9.01 Financial Statements and Exhibits.

Exhibits

99.1 Press Release dated February 11, 2021

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AngioSoma, Inc.
Dated: February 25, 2021	By:  /s/ Alex K. Blankenship
	Name:  Alex K. Blankenship Title:  President and CEO

- 2 -

EX-99

Exhibit 99.1

Angiosoma and its Subsidiary Somaceuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent

Houston, February 11, 2021 -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”), through its wholly-owned subsidiary, SomaCeuticals, Inc., is pleased to announce that the Exclusive Global Multiple Sclerosis License Agreement dated August 23, 2020 has been amended and restated as of February 4, 2021 to give both parties a stronger and more robust platform to move synergistically forward to market and license Patent 10,619,592 issued to Fabrizio de Silvestri as inventor.

Fabrizio de Silvestri stated, “It is wonderful that Jim Katzaroff and his group are actively interviewing Contract Research Organizations as well as possible funding sources. This looks to be a very exciting and critical year for AngioSoma.”

“I am so delighted that Jim was able to complete this transaction in a favorable manner to both parties. Now Jim will work with alacrity towards trials, and if we receive favorable results, navigate towards commercialization,” stated Alexanderia Blankenship, CEO and President of the Company.

About AngioSoma, Inc.

AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality supplement products and medical devices to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals^TM. Learn more at www.muscles4U.com and htttps://muscles4u.blogstop.com. Stay up to date at Twitter: @tweetmuscles4u, Instagram and Facebook.

Notice Regarding Forward Looking Statements

This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

CONTACT

AngioSoma, Inc.

James C. Katzaroff

President, SomaCeuticals, Inc.

(832) 781-8521